Biotech Buzz

Lynn Tyler wrote an article in the January issue of AIPLA Biotechnology Committee’s “Biotech Buzz” quarterly e-newsletter. The article discussed Valeant Pharm. N.A. LLC v. Mylan Pharm., Inc., in which the Federal Circuit held that, for venue purposes in Hatch-Waxman cases, an act of infringement occurs only in districts where actions related to the submission of an Abbreviated New Drug Application (ANDA) occur.